Cancer
Guardant Health Secures FDA Clearance for Expanded Liquid Biopsy Test
According to a recent report on MedTechDive, Guardant Health has received U.S. Food and Drug Administration (FDA) approval for an updated version of its liquid
Otsuka’s Voyxact Advances IgA Nephropathy Treatment Landscape with Phase 3 Data
- June 9, 2026
Duchenne Families Made the Sacrifices Asked. FDA Withheld the Hope.
FDA Extends Review of AstraZeneca’s Investigational Breast Cancer Therapy
HAYA Therapeutics Advances First-in-Class RNA Therapy Into Phase 1 for Cardiac Fibrosis in nHCM
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
porphyria
Her Final Year: What Love Looked Like When We Didn’t Have Answers
Editor’s Note: Patient Worthy is honored to present this story by Heather Doyle, originally published by the United Porphyrias Association. To see the article in
Breast Cancer
Beyond Your Grip
Editor’s Note: This piece, originally written by Kayla DeSonier, was shared with us by our friends at Elephants & Tea. To see the article in
Neurofibromatosis Type 2
The Silent Struggle – Mental Wellness in NF2 Surgery
Editor’s Note: This article was shared with us by our friends at the Cure NF2 Foundation, in honor of May 22nd being World NF2 Awareness
Colorectal cancer
Merck and Exelixis Team Up to Transform Treatment for High-Risk Colorectal Cancer Patients
Exelixis has taken a major step forward in its colorectal cancer development pipeline by securing supplies of Merck’s Keytruda for an upcoming phase 3 clinical
Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy: Coping and Caring
Betty Vertin is a mother, writer and a fierce defender of the decisions she and her husband Jason made about the seven children they brought
Rare Disease
A Glance at 2025-2026 Flu Seasons
According to the CDC, a look back at April 2026 cumulative reports showed more than 139 pediatric deaths with approximately 250,000 people hospitalized. In simple
McCune-Albright Syndrome
Breakthrough Recognition: Atossa’s (Z)-Endoxifen Earns FDA Rare Pediatric Disease Designation for McCune-Albright Syndrome
Atossa Therapeutics Inc. has achieved a significant regulatory milestone with the U.S. Food and Drug Administration’s grant of Rare Pediatric Disease (RPD) designation to (Z)-endoxifen
Acute Myeloid Leukemia
New Hopes for Acute Myeloid Leukemia
An article from University of Michigan highlighted Jolanta Grembecka and her husband Tomasz Cierpicki, both assistant professors in U of M’s Department of Pathology, who
Ehlers-Danlos Syndrome
Buy Art. Fund Science. Change Lives
Milenia Makani is an abstract artist living in London. She lives with Hypermobile Ehlers-Danlos Syndrome (hEDS), and has launched an international art fundraiser to support
Cancer
When Breakthrough Drugs Need a New Home: Inside the Arvinas-Rigel Partnership
What happens when a pharmaceutical first-mover discovers its historic achievement may not be a blockbuster? Arvinas and Pfizer found an answer this week by handing
Parkinson's Disease
Claudine’s Journey with Parkinson’s Disease
What is Parkinson’s Disease – known as PD for short? Parkinson’s Disease was first discovered in 1817 by a British doctor named James Parkinson. From
Bipolar disorder
The Prevalence of Tick Infections in Pediatric Bipolar Disorders
A recent article by Dr. Rosalie Greenberg explores the possible relationship of infections caused by ticks and psychiatric conditions in children, including PANS or PANDA
Epidermolysis Bullosa
Expanding Hope for Rare Skin Disease: CHOP Becomes Sixth Treatment Center for Revolutionary ZEVASKYN Gene Therapy
Abeona Therapeutics Inc. has announced a significant expansion in access to ZEVASKYN, marking the activation of Children’s Hospital of Philadelphia (CHOP) as the sixth Qualified
Duchenne Muscular Dystrophy
Regenxbio Reports Positive Pivotal Data for Gene Therapy RGX-202 in Duchenne Muscular Dystrophy
As reported on PharmaBiz, Regenxbio has announced encouraging topline findings from the pivotal Phase III portion of its ongoing AFFINITY DUCHENNE clinical program evaluating RGX-202,
Sickle Cell Disease
Canadian Biotech Biossil Identifying Potentially Overlooked Drug Candidates
Biossil, based in Toronto and co-founded by Dr. Alexander Mosa (Chair, CSO and co-founder) and Anthony Mouchantaf (CEO and co-founder), is making headway for rare
Rare Disease
Poolbeg Pharma Expands Global IP Position with Canadian Patent for POLB 001 in CRS
As reported on PharmaTimes, Poolbeg Pharma has secured a Canadian patent protecting the use of p38 MAPK inhibitors, including its lead candidate POLB 001, for preventing
Rare Disease
How to Advocate for Yourself During Appointments
Editor’s Note: This story was originally published on Linked-In and is shared with permission by Olga Lucia Torres. She waited an hour and fifteen minutes to
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
Multifocal motor neuropathy (MMN) is a rare neurological condition that can cause progressive muscle weakness and impact everyday activities. Because MMN is often misunderstood or mistaken for other conditions, awareness and education are important.
Swipe to learn more about MMN. Click here: bit.ly/4e8rksp or click the link in our bio to share your story.
#multifocalmotorneuropathy #mmn #shareyourstory #PatientWorthy
Healthcare has a way of teaching skills you never saw coming. How many squares can you check off? If you got a BINGO, let us know in the comments! 🅱️ ℹ️ 🆖 🅾️
And if you've picked up a healthcare skill that isn't on our card, share it with us. Your experience might be the one that makes someone else feel see.
#patientadvocacy #communitymatters #PatientWorthy
Today is Batten Disease Awareness Day.
Join us in raising awareness, fostering understanding, and supporting the individuals, families, and communities impacted by Batten disease!
#battendisease #battendiseaseawareness #rarediseaseoftheweek #RareDisease #rarediseaseawareness #PatientWorthy
